Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
scFv(MSLN) refers to a single-chain variable fragment (scFv) designed to specifically bind to mesothelin (MSLN), a cell-surface glycoprotein that is highly expressed in several solid tumors, including mesothelioma, pancreatic adenocarcinoma, and ovarian cancer, while showing limited expression in normal tissues. As a recombinant protein, it consists of the variable heavy (VH) and light (VL) chains of an anti-mesothelin monoclonal antibody joined by a flexible peptide linker. This fragment serves as a critical targeting moiety in various therapeutic modalities, most notably as the extracellular antigen-recognition domain of chimeric antigen receptor (CAR) T-cell therapies and as a component of recombinant immunotoxins or bispecific antibodies. By binding to MSLN, the scFv facilitates the localized delivery of cytotoxic effects to tumor cells by directing effector cells or payloads to the tumor microenvironment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-mesothelin single-chain variable fragment.